Eli Lilly promises additional $1.6b manufacturing investment
A total $3.7 billion investment at LEAP Innovation Park in the US is Eli Lilly and Company’s largest manufacturing investment at a single location in its history.
List view / Grid view
A total $3.7 billion investment at LEAP Innovation Park in the US is Eli Lilly and Company’s largest manufacturing investment at a single location in its history.
The number of potential clinical trial participants increased from over 51,000 to 1.7 million after researchers applied a new approach to improve eligibility.
Here, Edward C Tidswell, Executive Director Quality Assurance at Merck & Co, Inc., discusses the microbiology challenges for industry, pharmaceutical companies and microbiologists themselves.
A report on the UK's 2022 Life Sciences recruitment market revealed laboratory was the busiest scientific function among in-demand roles.
Three all-female key leaders in Europe have been hired by Velocity Clinical Research, the largest clinical sites business globally.
The pharmaceutical industry is bolstering aid for student research training in the UK, according to a survey produced by The Association of the British Pharmaceutical Industry (ABPI).
The Irish biopharmaceutical plant was given a special update for its pivotal 20th anniversary, expanding the site to offer its future workforce training in new technology.
Dr Eric Hughes will join Teva as Executive Vice President, Global R&D and Chief Medical Officer in August, assuming the role from Dr Hafrun Fridriksdottir, who has been with Teva for 25 years.
BIO International Convention 2022 shared the latest insights into diversity, equity and inclusion (DEI) in the biotechnology industry this week.
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
According to Takeda, its new strategic leadership changes will ensure the continued growth and competitiveness of the company.
Dr William Pao will assume his role as Executive Vice President and Chief Development Officer at Pfizer in March 2022, replaced at Roche by Dr Hans Clevers.
Tony Wood will assume accountability for R&D across GSK’s portfolio and pipeline from Dr Hal Barron on 1 August 2022.
In this in-depth focus, experts discuss how a future skills shortage may impact the biopharma industry and the key considerations when validating assays and analytical methods for ATMPs.
Bristol Myers Squibb (BMS)’s Tomorrow’s Innovators programme will promote the recruitment of Black talent into the biopharma industry.